FIELD: biotechnology.
SUBSTANCE: invention relates to a bispecific antibody for treating cancer, e.g., such as prostate cancer, lung cancer, NSCLC, melanoma, lymphoma, breast cancer, head and neck cancer, RCC, or ovarian cancer. The bispecific antibody comprises a binding domain binding a cell surface protein and a domain for inhibiting vascular endothelial growth factor (VEGF).
EFFECT: antibody applicable for treating different types of cancer.
16 cl, 16 dwg, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
| MOLECULES BINDING WITH CD38 AND PD-L1 | 2017 |
|
RU2764201C2 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| BISPECIFIC ANTIBODIES AND METHODS FOR THEIR PRODUCTION AND USE | 2018 |
|
RU2787783C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| ANTI-PD-L1 ANTIBODY FOR PD-L1 DETECTION | 2018 |
|
RU2758723C2 |
